The ‘Increasing Access to Biosimilar Act of 2023’ (HR 1352) was introduced into the US House of Representatives. The bill, if passed by Congress, would ‘require the Secretary of Health and Human Services to establish a demonstration project to increase access to biosimilar biological products under the Medicare program’. Its purpose is ‘to evaluate the benefits of providing a shared savings payment for biosimilar biological products’. The bill has been praised by the Biosimilars Forum.
Increasing Access to Biosimilar Act introduced to US House of Representatives
